News | January 07, 2024
AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
The deal includes upfront payments, milestone payments and ongoing royalties
The deal includes upfront payments, milestone payments and ongoing royalties
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
The company has received five final approvals
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
